← Back to Search
Initial Analysis Of The International Association For The Study Of Lung Cancer Mesothelioma Database
V. Rusch, D. Giroux, C. Kennedy, E. Ruffini, A. K. Cangir, D. Rice, H. Pass, H. Asamura, D. Waller, J. Edwards, W. Weder, H. Hoffmann, J. Van Meerbeeck
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Background: The current staging system for malignant pleural mesothelioma (MPM) is controversial. To plan revisions of this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. Initial analyses focus on patients managed surgically. Methods: Participation was solicited from centers known to have MPM registries. Common data elements were analyzed by the International Association for the Study of Lung Cancer Staging Committee Statistical Center. Survival was analyzed by the Kaplan–Meier method, prognostic factors by log rank and Cox regression model. p Value less than 0.05 was significant. Results: Data included 3101 patients (15 centers, 4 continents). Demographics: median age 63 years, 79% men, 62.3% epithelioid tumor. Best tumor, node, metastasis (bTNM) stages were: I (11%), II, (21%), III (48%), and IV (20%). Curative-intent surgery was performed in 1494 patients (64.5%). Median survivals by clinical TNM and pathological TNM were similar: stage I, 21 months; stage II, 19 months; stage III, 16 months; and stage IV, 12 months. Median survival by histology: epithelioid 19 months, biphasic 13 months, and sarcomatoid 8 months. By multivariable analyses, significant differences in overall survival were seen for: T4 versus T3 and T3 versus T2 but not T2 versus T1; N0 versus N1 and N2 but not N1 versus N2; stages III and IV versus I but not II versus I; epithelioid histology versus other; age of female versus age of male; and palliative versus curative-intent surgery. Conclusions: This is the largest international database examining outcomes in surgically managed MPM patients. Survival differences reported from smaller databases are confirmed but suggest the need to revise tumor and node staging.
This paper references
Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2008)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
TNM Classification of Malignant Tumours
L. Sobin (1987)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
P. Goldstraw (2007)
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A Scherpereel (2010)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
Japan Labour, Health, and Welfare Organization Hospitals (Rosai Hospitals
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
AJCC Cancer Staging Manual
M. B. Amin (2002)
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
The Geoform disease-specific annuloplasty system: a finite element study.
E. Votta (2007)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Extrapleural pneumonectomy for malignant mesothelioma.
D. Sugarbaker (1997)
Queen's Cancer Research Institute
Should we screen for endometrial cancer?
I. Vergote (2011)
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
T. Yamanaka (2009)
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma--institutional review and current update.
C. Cao (2011)
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2007)
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
Hisao Asamura, Chair Elect
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
根治的前立腺全摘術における神経移植 : Memorial Sloan-Kettering Cancer Centerの経験
大堀 理 (2000)
Threedimensional evaluation of chemotherapy response in malignant pleural mesothelioma
G Ak (2010)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
A. Nakas (2010)
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Initial Analysis of IASLC Mesothelioma Database Memorial Sloan-Kettering Cancer Center
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
This paper is referenced by
BAP1: Not just a BRCA1-associated protein.
Bryan H. Louie (2020)
The eighth TNM classification for malignant pleural mesothelioma.
L. Berzenji (2018)
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
S. Armato (2019)
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
L. Harling (2019)
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence‐Based Proposal
G. Pelosi (2018)
PROGRESS AND CHALLENGES IN MESOTHELIOMA: FROM BENCH TO BEDSIDE Authors
K. Blyth (2017)
Other Thoracic Malignancies
B. Tieu (2018)
Oncolytic Viral Therapy for Mesothelioma
D. Pease (2017)
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
Larry T Nickell (2014)
The Staging of Malignant Pleural Mesothelioma.
Caleb J Euhus (2020)
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
Traitement du mésothéliome pleural malin en 2016
A. Scherpereel (2016)
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period
A. Domen (2017)
The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
Akash M Patel (2017)
Genomic Landscape of Malignant Mesotheliomas
S. Kato (2016)
Therapeutic R2 resection for pleural mesothelioma.
D. Nguyen (2018)
Surgery in Malignant Pleural Mesothelioma
R. Bueno (2018)
Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.
Erika G Odisio (2017)
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
Malignant Pleural Mesothelioma: Rationale for a New TNM Classification
C. D. Laet (2014)
Staging in the era of international databases: documented improvements with remaining challenges.
R. Cameron (2018)
Perspective on malignant pleural mesothelioma diagnosis and treatment.
Ori Wald (2016)
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
H. Batırel (2018)
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
L. Lang-Lazdunski (2015)
Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
C. Simone (2014)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.
G. Utkan (2013)
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
The Immunogenic Effect of Local Radiation Therapy in a Murine Model of Mesothelioma
de la Maza Borja (2015)
Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.
V. Verma (2019)See more